Increased expression of CCL18 has been observed in various malignancies and in the urine samples of patients with bladder cancer (BC). However, the roles of CCL18 in the development, progression and metastasis of BC remain unclear. The present study demonstrated that CCL18 expression was significantly associated with advanced clinical stages of BC. Furthermore, exogenous CCL18 promoted cell invasion and migration, and induced cell epithelial-mesenchymal transition (EMT) in BC cells. Western blotting demonstrated that E-cadherin, an epithelial marker, was decreased, whereas matrix metalloproteinase (MMP)-2 and vascular endothelial growth factor (VEGF)-C were increased in CCL18-treated cells. Blocking CCR8 via a small molecule inhibitor or short hairpin (sh)RNA mitigated the decrease in E-cadherin, and increase in MMP-2 and VEGF-C, caused by human recombinant (r)CCL18. CCR8 knockdown by shRNA reversed rCCL18-induced cancer cell invasion, migration and EMT. In conclusion, these data suggested that CCL18 may promote migration, invasion and EMT by binding CCR8 in BC cells. Inhibition of CCL18 activity by blocking CCR8 could be a potential therapeutic strategy for preventing the progression of BC.

Introduction

Bladder cancer (BC) is the fourth most common type of cancer in men in the United States and is responsible for ~150,000 cases of mortality worldwide; therefore, it is considered an important health problem (1,2). Approximately 75% of patients have non-muscle-invasive BC (NMIBC) (Ta, T1) and 25% have muscle-invasive BC (≥T2). An important clinical issue is the high rate of recurrence associated with NMIBC. Although radical cystectomy and pelvic lymphadenectomy can be performed, a high percentage of patients progress to advanced invasive tumors. Tumors at a high risk for recurrence and progression require neoadjuvant treatment (3).

Chemokine (C-C motif) ligand (CCL)18 is a C-C chemokine that is highly expressed in human lung tissues and plasma; CCL18 serves numerous functions in immune modulation and cancer progression (4). Recent studies have reported that increased expression levels of CCL18 are observed in various malignancies, including ovarian cancer, lung cancer, oral squamous cell cancer and breast cancer (5-8). It has also been suggested that CCL18 acts as a potential urinary biomarker in BC (9,10); however, the molecular mechanisms underlying the effects of CCL18 on BC remain unknown. C-C motif receptor 8 (CCR8) is a G protein-coupled receptor, which is known to be expressed by immune cells, including T-helper 2 lymphocytes, natural killer cells, and monocytes (11). In humans, CCR8 is selectively activated by CCL18 (12). Recently, Islam et al reported that CCR8 is a functional receptor for CCL18 (13).

The present study revealed that CCL18 promoted the migration and invasion of BC cells. However, the underlying molecular mechanisms by which CCL18 induces epithelial-mesenchymal transition (EMT) in BC cells and contributes to cancer cell invasion have not been identified. In addition, the present study demonstrated that excessive expression of CCL18 in tumor tissues was associated with tumor stage and poor prognosis in patients with BC. Furthermore, the present data indicated that CCL18 may promote migration, invasion and EMT through the G protein-coupled receptor chemokine CCR8.

Materials and methods

Gene expression profiling. Expression of CCL18 in BC (BLCA dataset) was checked using The Cancer Genome Atlas (TCGA) data. TCGA, launched by the National Institutes...
of Health (NIH, Bethesda, MD, USA), is a publicly funded project that comprises a comprehensive ‘atlas’ of cancer genomic profiles. The expression levels of CCL18 in 404 patients with BC compared with 28 normal samples from TCGA database and GTEx were analyzed using the GEPIA web server (14). The Pathology Atlas from the Human Protein Atlas (www.proteinatlas.org/pathology) was used to perform analyses based on the mRNA expression levels of CCL18 in BC tissue and the clinical outcomes (survival). The data in the Pathology Atlas are based on the integration of publicly available data from TCGA. In addition, gene expression profiling studies involving several clinical samples were performed to analyze the expression of CCL18 in a dataset available through the Gene Expression Omnibus (GSE31684; https://www.ncbi.nlm.nih.gov/geo/) (15).

Patients and tissue samples. The present study was approved by the Research Ethics Committee of the First Affiliated Hospital, Nanchang University (Nanchang, China). Informed consent was obtained from all patients. All specimens were handled and anonymized according to ethical and legal standards. Immunohistochemical analysis of CCL18 was conducted using 64 primary BC tissues and 30 adjacent noncancerous bladder tissues. Detailed information on the clinical features of all patients in this study is presented in Table I.

Cell culture and treatment. The 5637 human BC cell line was purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Shanghai Institute of Cell Biology (Shanghai, China) and was maintained in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Media were supplemented with 10% heat-inactivated fetal bovine serum (FBS; HyClone; GE Healthcare Life Sciences, Logan, UT, USA), 100 U/ml penicillin and 100 µg/ml streptomycin at 37˚C in a humidified incubator containing 5% CO2. The small molecule CCR8 inhibitor R243 (cat. no. AOB2014) was purchased from AOBIOUS, Inc. (Gloucester, MA, USA). For chemokine treatment, 5637 cells pretreated with or without R243 (5 µM) for 6 h at 37˚C/5% carbon dioxide (16), were exposed to 50 or 100 ng/ml CCL18 (PeproTech, Inc., Rockville, MD, USA) for 36 h.

Short hairpin (sh)RNA transfection. For transfection, 5637 cells were plated in 6-well plates at 2x10^4/well. The human CCR8 shRNA plasmid and non-target shRNA (NT shRNA) were obtained from Invitrogen; Thermo Fisher Scientific, Inc. The targeted sequences were: Human CCR8 (5'-CCG GGG ATT CAT ACT TGC GAG CAG GTT CAA GGT GAG TCA TAAT CCT TTT TTT TGT G-3') and non-target (NT) shRNA (5'-CCG GCA ACA AGA GTG GAC AAG CAC AAT CGA AGT GGT GTC TTT CAT TTT GTG TTT TTT TTT TTT 3'). Once the 5637 cells reached 50-60% confluence, 1.25 µg/ml CCR8 shRNA and NT shRNA were transfected using Lipofectamine® 2000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and Opti-MEM medium (Gibco; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. A total of 6 h post-transfection, the medium was replaced with fresh medium containing 10% FBS. NT shRNA was used as the negative control.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. A total of 24, 48 and 72 h post-transfection, total RNA was extracted from 5637 cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and CDNA was synthesized using a Takara PrimeScript RT reagent kit (Takara Bio, Inc., Otsu, Japan) according to manufacturer's protocols. qPCR was performed using SYBR Premix Ex Taq kit (Takara Bio, Inc., Otsu, Japan) in the ABI Prism® 7500 real-time PCR system (Thermo Fisher Scientific, Inc.). The thermocycling conditions were initial denaturation (1 cycle, 95˚C, 30 sec), PCR reaction (40 cycles, 95˚C, 5 sec, and 60˚C, 30 sec for annealing and elongation). The data of RT-qPCR were normalized against an internal control β-actin and relative expression levels were evaluated using the 2^(-ΔΔCq) method and then expressed as fold changes (17). The oligonucleotide sequences of the RT-qPCR primers are listed in Table II.

Western blot analysis. Total proteins were extracted from cells using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China). Proteins were quantified using a Pierce bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Inc.), followed by western blot analysis. 40 µg proteins from cell lysates were subjected to 12% SDS-PAGE. Once proteins were transferred to nitrocellulose membranes, they were incubated with antibodies targeting β-actin (cat. no. 58169, 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA), CCR8 (cat. no. ab32131, 1:500; Abcam, Cambridge, UK), E-cadherin (cat. no. 3195, 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA), matrix metalloproteinase (MMP)-2 (cat. no. 40994, 1:1,000; Cell Signaling Technology, Inc.) and vascular endothelial growth factor (VEGF)-C (cat. no. 2445, 1:1,000; Cell Signaling Technology, Inc.), followed by incubation with a horseradish peroxidase-labeled goat anti-rabbit secondary antibody (cat. no. ab6721, 1:3,000; Abcam) for 1.5 h at room temperature. Protein bands were visualized by Millipore enhanced chemiluminescence (cat. no. WBLKLS0500; EMD Millipore, Billerica, MA, USA). ImageJ 1.45 software (NIH) was used to perform densitometric analysis of each band.

Immunohistochemistry. Tissue sections from paraffin-embedded bladder cancer were dewaxed in xylene and rehydrated in a graded alcohol series. Following microwave-induced antigen retrieval (Tris-EDTA pH 9.0), the slides were washed with PBS and incubated with primary antibody against CCL18 (cat. no. ab104867, 1:200; Abcam) overnight at 4˚C. The sections were incubated with secondary antibody at room temperature. for 30 min after washing with PBST. Color detection was performed by liquid DAB+ substrate chromogen system (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) according to the manufacturer's protocols. Slides were counterstained with hematoxylin. Hemalum was used to stain nuclei of cells blue at room temperature for 20 sec. Immunohistochemical images of CCL18 expression were analyzed according to a previous study (18). Representative areas with 5 or 20 CCL18 cells per x400 high-power field were chosen and images were captured randomly as references for grading. The densities of CCL18+ cells were graded as follows: Grade 1, <5 positive cells/microscopic field; grade 2, 5-20
Table I. Association of CCL18 expression with the clinicopathological characteristics of bladder cancer.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>High (Grade ≥2) (n=37)</th>
<th>Low (Grade &lt;1) (n=27)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age*, mean ± SD</td>
<td>62.7±9.1</td>
<td>64.6±8.8</td>
<td>0.403</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>6 (54.5)</td>
<td>5 (45.5)</td>
<td>0.809</td>
</tr>
<tr>
<td>Male</td>
<td>31 (58.5)</td>
<td>22 (41.5)</td>
<td></td>
</tr>
<tr>
<td>Tumor stage, n (%)</td>
<td></td>
<td></td>
<td>0.018</td>
</tr>
<tr>
<td>T1</td>
<td>10 (47.6)</td>
<td>11 (52.4)</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>10 (43.5)</td>
<td>13 (56.5)</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>9 (75.0)</td>
<td>3 (25.0)</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>8 (100.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Tumor grade, n (%)</td>
<td></td>
<td></td>
<td>0.447</td>
</tr>
<tr>
<td>Low grade</td>
<td>12 (48.0)</td>
<td>13 (52.0)</td>
<td></td>
</tr>
<tr>
<td>High grade</td>
<td>25 (64.1)</td>
<td>14 (35.9)</td>
<td></td>
</tr>
</tbody>
</table>

Age data were analyzed by a *Student's t-test. Other data were analyzed using a Fisher's exact test (two-sided) or χ² Pearson (two-sided) test.

Table II. Oligonucleotide sequences for polymerase chain reaction amplification.

<table>
<thead>
<tr>
<th>Gene</th>
<th>NCBI no.</th>
<th>Sequence (5'-3')</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCR8</td>
<td>NM_005201.3</td>
<td>F: GTGTGACAACAGTGACCGACT R: CTTCTTGCAAGACCACAAGGAC</td>
<td>173</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>NM_001317186.1</td>
<td>F: AGCTGCCAGAAAAATGAAAAAGG R: GGTGATGCGGAATGGCGTTCCT</td>
<td>203</td>
</tr>
<tr>
<td>MMP-2</td>
<td>NM_001302510.1</td>
<td>F: CCTCTCCACTGCTTCTGATA R: TGGGAGCAGTACGTCAGCA</td>
<td>129</td>
</tr>
<tr>
<td>VEGF-C</td>
<td>NM_005429.2</td>
<td>F: GGGCTGCCAACATAACAGAGAA R: CCCACATCTTACACACCTCC</td>
<td>159</td>
</tr>
<tr>
<td>β-actin</td>
<td>NM_001101.3</td>
<td>F: CATGTACGGGTCTATCCAGGCG R: CTCCTTAATGTCACGCAGAT</td>
<td>250</td>
</tr>
</tbody>
</table>

CCR8, chemokine (C-C motif) receptor 8; F, forward; MMP-2, matrix metalloproteinase-2; NCBI, National Center for Biotechnology Information; R, reverse; VEGF-C, vascular endothelial growth factor-C.

cells/field; and grade 3, >20 cells/field. Grade 1 was considered to be low-level CCL18, and grades 2 and 3 were considered to be high-level CCL18.

Cell migration and Transwell assays. Cell migration was determined using a wound-healing assay. Briefly, 5637 cells were seeded in six-well culture dishes and cultured at 37°C to form a confluent monolayer. After transfection with or without CCR8 shRNA for 24 h, and a wound was made by scratching the monolayer with a 10 µl pipette tip. The wounded monolayer was then washed three times with PBS to remove cell debris and treated with CCL18 for 24 h at 37°C. After scratching, the area of the cell-free scratch was imaged under an Olympus CKX41 inverted microscope (Olympus Corporation, Tokyo, Japan) at 0 and 24 h. Cell invasive capacities were measured using a Transwell assay (Corning Incorporated, Corning, NY, USA). Briefly, 5637 cells were treated with CCL18 and/or transfected with CCR8 shRNA for 24 h, and were then seeded in the upper chamber of the Transwell system. The upper chamber of the insert was precoated with 0.1 ml (300 µg/ml) Matrigel matrix (Corning Incorporated) for the invasion assay. The invaded cells on the underside of the membrane were counted. In this assay, prepared cells were seeded in the upper chamber with serum-free medium and the medium of the lower chamber was supplemented with 10% FBS as a chemoattractant. Following incubation for 24 h, the cells were fixed with 4% formaldehyde at 37°C for 30 min. Cells that did not invade through the pores were removed with a cotton swab. Cells that had invaded to the lower surface of the membrane were stained with crystal violet at 37°C for 15 min. Finally, images of five representative fields
at x100 magnification were randomly captured using a light microscope (Carl Zeiss AG, Oberkochen, Germany) and the number of cells in each well was semi-quantified.

Statistical analysis. All data are presented as the means ± standard deviation in at least three replicates per group. Statistical analysis was performed to determine the significance of the differences between groups using one-way analysis of variance (with post hoc Turkey’s honest significant difference test) or Student’s t-test. χ² analysis and Fisher’s exact test were used to examine the association between CCL18 expression and the clinicopathological features of patients with BC. The effects of CCL18 expression levels on survival were estimated using the Kaplan-Meier method and were compared by the log-rank test. Wilcoxon-signed rank test was used to compare CCL18 expression between 30 paired cancerous and noncancerous tissues of patients with BC. All statistical analyses were performed using GraphPad Prism 7.00 software for Windows (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Association of CCL18 expression with the clinicopathological characteristics of BC. To assess whether CCL18 may
be involved in the development of BC, this study first investigated the mRNA expression levels of CCL18 using TCGA dataset. As illustrated in Fig. 1A, the mRNA expression levels of CCL18 were significantly higher in BC tissues compared with in nontumor tissues. In addition, CCL18 mRNA expression was higher in BC tissues at stages III and IV compared with at stage II (Fig. 1B and C). Kaplan-Meier analysis indicated that higher CCL18 expression was associated with worse patient survival (log-rank test, P=0.0487; Fig. 1D). Subsequently, the expression of CCL18 was investigated in BC tissues using immunohistochemistry. As reported in a previous study (10), there was no epithelial staining for CCL18; however, inflammatory cells in the stroma were CCL18-positive. It was revealed that CCL18 expression was higher in the majority of cancerous samples compared with in noncancerous tissues (Fig. 1E). Furthermore, the protein expression levels of CCL18 were detected in tissues obtained from 30 patients with BC by immunohistochemical staining. The results demonstrated that CCL18 expression was significantly stronger in the majority of BC tissues compared with in paired normal tissues (Fig. 1F). As shown in Table I, higher CCL18 expression was associated with higher pathological stages (P<0.05). These data suggested that CCL18 was elevated in BC tissues and may be associated with the progression of BC.

CCL18 regulates the expression of E-cadherin, MMP2 and VEGF-C in 5637 BC cells. EMT is thought to serve a key role in the invasion and metastasis of numerous types of tumor (19). EMT is an evolutionarily conserved developmental program, which is believed to have a critical role in carcinogenesis and tumor metastasis by enhancing motility and invasion. Our previous study revealed that VEGF-C, MMP-2 and MMP-9 are immunosuppressive factors, which serve important roles in BC invasion and metastasis (20). To determine whether CCL18 enhanced BC invasion and metastasis through EMT, and by altering MMP-2 and VEGF-C expression, 5637 BC cells were treated with CCL18. Following treatment of 5637 BC cells with 50 or 100 ng/ml CCL18 for 36 h, the expression levels of E-cadherin were significantly lower, and the expression levels of MMP-2 and VEGF-C were higher compared with in the control group (Fig. 2).

CCR8 is required for migration and invasion of BC cells via CCL18. CCL18 has numerous receptors, including PITPNM family member 3 (PITPNM3) and G protein-coupled estrogen receptor 1 (GPR30), which mediate CCL18-induced migration of cancer cells, and promote tumor invasion and metastasis (8,21). Recently, Islam et al reported that CCR8 is a functional receptor for CCL18 (13). To identify whether CCR8 was associated with CCL18-induced tumor invasion and EMT, this study examined the expression levels of E-cadherin, MMP-2 and VEGF-C in 5637 BC cells treated with a small molecule CCR8 inhibitor, R243, or transfected with CCR8 shRNA, followed by CCL18 treatment (Figs. 2 and 3). As shown in Fig. 2, R243 reversed the decreased levels of E-cadherin and increased levels of MMP-2 and VEGF-C caused by CCL18, without affecting CCR8 levels. The results of RT-qPCR confirmed that the mRNA expression levels of CCR8 were downregulated by CCR8 shRNA (Fig. 3A); CCR8 protein expression was also reduced in response to CCR8 shRNA (Fig. 3D). RT-qPCR analysis revealed that the mRNA expression levels of E-cadherin

Figure 2. CCL18 affects the expression levels of E-cadherin, MMP-2 and VEGF-C. (A and B) 5637 bladder cancer cells were treated with PBS or CCL18 (50 or 100 ng/ml) for 36 h, with or without pretreatment with the CCR8 inhibitor R243. Protein expression levels of E-cadherin, MMP-2 and VEGF-C were detected in 5637 cells by western blot analysis. *P<0.05 compared with the 50 ng/ml CCL18 and NC groups; **P<0.05 compared with the NC group. CCL18, chemokine (C-C motif) ligand 18; MMP-2, matrix metalloproteinase-2; NC, normal control; VEGF-C, vascular endothelial growth factor-C.
were increased, whereas those of MMP-2 and VEGF-C were decreased compared with in cells transfected with NT shRNA (Fig. 3B). Similar results were revealed by western blot analysis for the protein expression levels of E-cadherin,
MMP-2 and VEGF-C (Fig. 3C and D). Subsequently, the migratory and invasive abilities of BC cells were reduced in CCR8-knockdown cells compared with in control cells (Fig. 4A-D).

**Discussion**

To the best of our knowledge, the present study is the first to demonstrate that CCL18 may be frequently overexpressed in BC. Furthermore, it was revealed that CCL18 enhanced bladder cancer cell invasion, migration and EMT. CCL18 has numerous receptors, including PITPNM3 (8) and GPR30 (21), which mediate CCL18-induced migration of cancer cells, and promote tumor invasion and metastasis. CCL18 activates proline-rich tyrosine kinase 2 and the Src kinase PITPNM3 by binding to PITPNM3, which is expressed in breast cancer cells, thereby promoting metastasis of breast cancer (8). However, the functional receptor for CCL18 that mediates BC cell invasion and migration remains unknown. Recently, Islam et al reported that CCR8 is a functional receptor for CCL18 (13). When CCL18 binds to CCR8, CCR8 is activated through G-protein signaling, inducing CCR8 internalization and activating cell chemotaxis and calcium flux in human CCR8-transfected cells. In the present study, it was further deduced that the G-protein coupled receptor CCR8 may mediate signaling by CCL18, and a potential mechanism underlying tumor regulation in BC was determined.

E-cadherin is an epithelial marker, the functional loss of which is a hallmark of EMT, which is thought to promote BC progression and metastasis (22). MMP-2 is considered a mesenchymal marker of EMT (23). In the present study, CCL18 was revealed to mediate EMT through MMP-2-dependent pathways.

MMPs are best known for their profound role in malignant transformation and metastasis via extracellular matrix disruption (24). MMP-2, which is a member of the MMP family, is associated with tumor invasion through degradation of the extracellular matrix and basement membrane. In BC, high MMP2 expression is strongly correlated with decreased survival (25). In addition, MMP2 is overexpressed at the invasive front and is associated with a higher tumor grade in BC (26).

Previous studies have reported that upregulation of the lymphangiogenic growth factor VEGF-C is positively correlated with regional lymph node metastasis and poor survival in BC (27-32). VEGF-C is a protein precursor that must be activated by a converting enzyme (proprotein convertases). VEGF-receptor 3 (VEGF-R3) is one of the receptors of VEGF-C, which promotes lymphangiogenesis, tumor cell migration, invasion and metastasis. Blocking VEGF-C signaling via either small interfering RNA or a VEGF-R3 antibody inhibits lymphatic-based metastatic spread of human malignancies (33).

Immunosuppressive factors can be secreted into the extracellular environment by tumor cells in an autocrine or paracrine fashion, resulting in deep immunosuppressive regions that are formed locally in tumor cells. Our previous study revealed that VEGF-C, MMP-2 and MMP-9, as immunosuppressive factors, serve important roles in BC invasion and metastasis (20). In the present study, it was demonstrated that the expression levels of VEGF-C and MMP-2 were elevated by CCL18 treatment. Furthermore, the mRNA expression levels of CCL18 were assessed in BC tissues according to TCGA data, and protein levels were detected by immunohistochemistry. The mRNA and protein expression levels of CCL18 were higher compared with in noncancerous bladder tissues. In the present cohort, CCL18 upregulation was associated with a high pathological grade. Furthermore, it was revealed that rCCL18 stimulation significantly enhanced the invasive potential of 5637 cells, and the CCL18 receptor, CCR8, mediated this activity in 5637 cells. Conversely, a CCR8 inhibitor or CCR8 shRNA abrogated the decreased levels of E-cadherin, and increased levels of MMP-2 and VEGF-C caused by CCL18. These data indicated that CCR8 may be associated with the oncogenic role of CCL18 in 5637 BC cells.

The CCR8 axis is associated with cancer progression in BC, renal carcinoma (34) and pancreatic cancer (35). R243 is a novel small molecule CCR8 inhibitor, which inhibits the effects of CCR8 in vivo and in vitro (16). CCR8 inhibition by R243 is able to counteract the phenotypes induced by extracellular vesicles decorated with CCL18 in glioblastoma cells (36). The present study demonstrated that the CCR8 inhibitor, R243, abrogated the effects of CCL18 on BC cells, thus suggesting a potential role for R243 in blocking the CCL18/CCR8 axis during BC progression. Although R243 is able to inhibit the effects of CCR8, the expression of CCR8 were unaffected in present study. Additionally, due to very low signal levels in a previous Biacore analysis, determination of intact R243 binding to immobilized CCR8 failed (16). Binding to the receptor or the site of action for R243 remains unclear. Therefore, in this study, CCR8 shRNA was selected, rather than R243, for use in cell migration and invasion experiments.

In conclusion, the present data offered convincing evidence to suggest that upregulation of CCL18 may be involved in the aggressive progression of BC partially through the G-protein-coupled receptor CCR8. These results provided information regarding the mechanisms underlying prevention of the progression of BC by inhibiting CCL18 activity via blocking CCR8. However, further studies are required to explore the detailed mechanisms underlying the effects of CCL18 and CCR8 on the regulation of BC progression.

**Acknowledgements**

Not applicable.

**Funding**

This study was supported by the National Natural Science Foundation of P.R. China (grant no. 81560419), the Natural Science Foundation of Jiangxi (grant no. 20151BAB205047) and the Jiangxi Province Infrastructure Facilities for Scientific Research Institutes (grant no. 20142BBA13038).

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.
Authors' contributions

XL, XX, WD, MH, YWu, ZZ and KZ performed the experiments and generated data. XL, ZZ, YWang, XC, XZ, LC and YL analyzed the data. GW and BF made substantial contributions to the design of the experiments. XL, XX and BF wrote the manuscript. All authors reviewed and approved the manuscript.

Ethics approval and consent to participate

The present study was approved by the Research Ethics Committee of the First Affiliated Hospital, Nanchang University (Nanchang, China). Informed consent was obtained from all patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.